Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for RT + NBTXR3 + Chemotherapy in Esophageal cancer. The expected timing is based on the latest available company guidance and may change.
06/02/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.